Can a cancer drug target a key gene loss in advanced prostate cancer?
NCT ID NCT06029998
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This phase 2 trial tests the drug bortezomib in 22 men with metastatic castration-resistant prostate cancer that has a specific genetic change called PTEN deletion. The main goal is to see if bortezomib can lower PSA levels by at least 30%. Participants receive bortezomib injections for up to 8 cycles of 21 days each.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute/University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bortezomib
What this could lead to
If successful, this could point toward a new treatment option for men with a specific genetic type of advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is a small, early-phase trial with only 22 participants, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects like nerve damage or low blood counts are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.